Filter Results:
(298)
Show Results For
- All HBS Web
(298)
- People (1)
- News (81)
- Research (187)
- Multimedia (4)
- Faculty Publications (124)
Show Results For
- All HBS Web
(298)
- People (1)
- News (81)
- Research (187)
- Multimedia (4)
- Faculty Publications (124)
- Profile
Jeremy King
As an undergraduate, Jeremy King pursued a degree in biology, studying ecology, genetics and animal behavior. Though he considered medicine a career, he found himself working with a very different animal. "I interned in the more... View Details
- 06 Sep 2016
- News
Connecting Past and Present
Family health was the impetus for Stanley Diamond (MBA 1958), founder of one of the world’s largest genealogy resources. “My family carries the beta thalassemia genetic trait,” a blood disorder. When my nephew was diagnosed, and we then... View Details
- 15 Jan 2018
- Research & Ideas
A Better Business Model for Fighting Cancer
question—it’s clear.” Simply put, inefficiencies in the development of precision medicine can best be addressed by a business-analysis approach. With the mapping of the human genome completed 15 years ago, the sci-fi concept of using a cancer patient’s View Details
- 01 Mar 2017
- News
Alumni Take Cold Calls in New York City
focused on 23andMe, whose sale of genetic testing kits directly to consumers was challenged by the Food & Drug Administration. Quelch, who coauthored the case, is also on the faculty of the Harvard T.H. Chan School of Public Health. The... View Details
- 15 Apr 2014
- First Look
First Look: April 15
Pooled Income Funds. Purchase this case: http://hbr.org/product/choosing-a-charitable-giving-vehicle/an/314073-PDF-ENG Harvard Business School Case 514-086 23andMe: Genetic Testing for Consumers (A) On November 22, 2013, the... View Details
Keywords: Sean Silverthorne
- 01 Jun 2018
- News
Floor It
The sci-fi future for cancer treatment has become a reality, with breakthrough therapies that can use a cancer patient’s genetic information to create personalized treatments or employ the body’s immune response to treat disease. But for... View Details
Keywords: Julia Hanna; illustration by Mengxin Li
- June 2005 (Revised July 2006)
- Background Note
Note on the Convergence Between Genomics & Information Technology
By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha
Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in... View Details
Keywords: Genetics; Information Technology; Business Model; Disruptive Innovation; Biotechnology Industry; Information Technology Industry; Semiconductor Industry; Medical Devices and Supplies Industry
Yoffie, David B., Dharmesh M Mehta, and Rachel Sha. "Note on the Convergence Between Genomics & Information Technology." Harvard Business School Background Note 705-500, June 2005. (Revised July 2006.)
- February 2008 (Revised August 2008)
- Case
EXACT Sciences Corp.: Commercializing a Diagnostic Test
This case addresses the challenges of commercializing molecular diagnostics. Along the way, it explains the technology, payment system, and the measures used to assess the value of a diagnostic test. View Details
Keywords: Health Testing and Trials; Genetics; Science-Based Business; Commercialization; Biotechnology Industry
Herzlinger, Regina E. "EXACT Sciences Corp.: Commercializing a Diagnostic Test." Harvard Business School Case 308-090, February 2008. (Revised August 2008.)
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
- 23 Nov 2010
- First Look
First Look: November 23
case:http://cb.hbsp.harvard.edu/cb/product/811014-PDF-ENG Generation Health: A Pioneer in Genetics Benefit Management (A) Robert F. Higgins, Jeffrey D. Marrazzo, and Rachel GordonHarvard Business School Case 810-007 Generation Health, a... View Details
Keywords: Sean Silverthorne
- Profile
Paris Wallace
Eric Boutin in 2008 in his last year at HBS. Good Start Genetics is now a successful late stage venture with more than 150 employees. The company offers a fertility diagnostic that allows parents to determine if their children are at risk... View Details
- 15 Dec 2015
- News
The Year in Ideas 2015
qualities, achieved through the controversial technology of genetic modification. Genetically modified foods, also known as GMOs, are a confusing topic for consumers. In the United States, 95 percent of the... View Details
- October 2011
- Case
Gene Sequencing: Staking a Position in an Expanding Industry
By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews
Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would... View Details
Keywords: Genetics; Business Growth and Maturation; Business Plan; Competition; Venture Capital; Biotechnology Industry
Hamermesh, Richard G., Mara Aspinall, and Phillip Andrews. "Gene Sequencing: Staking a Position in an Expanding Industry." Harvard Business School Case 812-004, October 2011.
- 02 Jul 2001
- Research & Ideas
Ray A. Goldberg
issues," he beams, "from land reform in Mexico to the development of the genetically modified tomato." "The genetic research revolution is changing our global economy and society more... View Details
- 01 Oct 2001
- News
Philip L. Yeo: The Next Big Thing
sciences and bioengineering. "In the next generation, we will know the genetic and molecular mechanisms of disease," Yeo declares. "Biomedical science will control and eradicate cancer and AIDS, and individualized medicine will be the... View Details
Keywords: Government
- 26 Jun 2000
- Research & Ideas
Presentation Round-Up
get out of the way. But we also have to be prepared. Where the market fails to provide the service, we have to step in." Genes On The Web In a discussion moderated by HBS Professor Josh Lerner, participants in the panel on "Genes on the Web" emphasized the positive... View Details
- 28 Dec 2016
- News
In Memoriam: Bill Bowes (MBA 1952)
the Harvard Stem Cell Institute as well as service on the advisory committee for the Harvard Partners Center for Genetics and Genomics. Bowes was named an HBS Alumni Achievement Award winner in 2009, and his gift to the School in 2012... View Details
- Web
Business Track | New Venture Competition
Venture Competition Winner, Business Track: Crop Diagnostix Crop Diagnostix is redefining precision agriculture through AI-powered, genetic insights. Team: Brandon Chi, MBA 2024; Joseph Swift; Amitesh Pratap; Leonie Luginbuehl. Play Video... View Details
- June 1997 (Revised September 1997)
- Case
Genset Initial Public Offering (B)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Supplements the (A) case. View Details
Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (B)." Harvard Business School Case 297-097, June 1997. (Revised September 1997.)
- June 1997 (Revised March 2001)
- Case
Genset Initial Public Offering (A)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research. View Details
Keywords: Business Model; Initial Public Offering; Genetics; Going Public; Management Teams; Biotechnology Industry; France; United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (A)." Harvard Business School Case 297-096, June 1997. (Revised March 2001.)